These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of zymosan on antioxidant and immune function of S180 tumor-bearing mice.
    Author: Liu XL, Lin N, Zan D, Yuan JJ, Cai DL.
    Journal: Cell Biochem Biophys; 2011 Jul; 60(3):225-9. PubMed ID: 21279551.
    Abstract:
    The objective is to study the effect of zymosan on antioxidant and immune function of S(180) tumor-bearing mice. Seventy Kunming mice were randomly divided into seven groups: a normal control group (NC), a tumor control group (TC), three dose groups of zymosan (low, medium, high), a cyclophosphamide (Cy) group, and a combination of zymosan and Cy group. The S(180) tumor-bearing mice model was established by the inoculation of cancer cell suspension subcutaneously in the mouse's right anterior limb. At the 19th day, malondialdehyde (MDA), glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) activity in liver homogenate were analyzed. The reverse transcriptase-polymerase chain reaction was used to determine the mRNA expression levels of IL-2, TNF-α, and TGF-β(1). The activity of GSH-Px and SOD in the liver increased with the dose of zymosan, whereas the activity of MDA significantly decreased in the higher-dose groups of zymosan, compared to the TC group (P < 0.01). In the zymosan groups, mRNA expression levels in tissues of S(180) tumor-bearing mice were significantly higher for TNF-α and IL-2, but lower for TGFβ(1) than in the Cy or TC group (P < 0.01). The high-dose of zymosan markedly showed a depressant effect on S(180) tumor, enhanced by the action of Cy that increased mRNA expression levels of TNF-α and IL-2. The mechanism of zymosan on the inhibition of tumor growth may be due to its ability to enhance the antioxidant and immune function in a dose-dependent manner.
    [Abstract] [Full Text] [Related] [New Search]